HALBERD CORP - HALB STOCK NEWS

Halberd Corporation has appointed Dr. Mitchell S. Felder as Chief Technical Officer, succeeding Dr. Patricio Reyes, who will continue as a consultant. Dr. Felder, a Board-Certified Neurologist with numerous patents related to disease eradication, will oversee testing in radio frequency and laser technologies. This transition is expected to enhance R&D efforts at Youngstown State University, focusing on eradicating E. coli bacteria as a precursor to tackling other pathogens, including COVID-19. Halberd holds several patents and applications relevant to its initiatives.

Halberd Corporation (OTC PINK:HALB) has filed a PCT application for its invention titled Treating and Curing Covid-19 Infection Utilizing a Laser. This international application enables patent protection across over 150 countries. CEO William A. Hartman stated this technology could revolutionize Covid-19 treatment through laser ablation methodology. The company is also initiating laser experimentation at Youngstown State University and holds exclusive rights to several patents and applications related to Covid-19 treatments, enhancing its position in the medical technology sector.

Halberd Corporation (OTC PINK:HALB) announced that its two patent-pending monoclonal antibodies have shown significant effectiveness against three SARS-CoV-2 mutations: Q498Y, P499T, and Q493K. Principal researcher Dr. Shawn Chen emphasized the strong neutralizing capabilities of these antibodies. Plans for mouse testing are underway to confirm laboratory results. CEO William Hartman expressed optimism about these antibodies potentially addressing key COVID-19 variants. Halberd holds various patent applications related to COVID-19 treatments and is in full compliance with OTC Market requirements.

Halberd Corporation (OTC PINK:HALB) has announced Dr. William G. Sturrus from Youngstown State University (YSU) will lead research in Radio Frequency (RF) technology aimed at eradicating infectious diseases. With over 30 years of experience, Dr. Sturrus's team, comprising faculty and students, is set to begin experiments shortly. This collaboration aims to prove that diseases can be eliminated from bodily fluids using RF waves combined with Halberd's patented processes. The technology promises minimal side effects compared to traditional treatments, paving the way for revolutionary medical advancements.

Halberd Corporation (OTC PINK: HALB) has filed an International Patent Cooperation Treaty (PCT) application for its invention titled Covid-19 Inflammatory Cytokine Storm Treatment. This application expands its patent protection across over 150 countries. The treatment aims to tackle Covid-19 and other diseases via a patented extracorporeal process, with current experiments being conducted in collaboration with GreenBioAZ and Youngstown State University. Halberd also holds exclusive rights to multiple related technologies and has filed various provisional patent applications concerning Covid-19 treatments.

Halberd Corporation (OTC PINK: HALB) reported significant progress in Q1 2021, showcasing a remarkable 17,500% stock appreciation over the past year and a 280% increase in the first quarter alone. Key accomplishments include developing patent-pending technologies for SARS-CoV-2, such as a novel fluorescent antibody and multiple antibodies targeting the Spike Protein. The company secured a $2 million funding commitment and maintained active investor communications. Goals for Q2 include enhancing corporate listings and initiating testing on various pathogens, maintaining momentum in innovation and shareholder value.

Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by successfully conjugating metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, maintaining its neutralizing properties. This development is crucial for utilizing radio frequency (RF) energy in disease eradication. Additionally, the company has shown efficacy in E. Coli antibodies, broadening its application scope. Chairman William A. Hartman emphasized the swift intellectual property protection and forthcoming lab tests with university partners to assess RF's effectiveness against disease antigens.

Halberd Corporation (OTC PINK:HALB) has compiled various peer-reviewed medical articles supporting the selection of nutraceuticals for its VITA-SHIELD-MAX Immune Booster. CEO William A. Hartman emphasized the consensus on ingredients to enhance health and well-being. This compilation will be shared with sales teams and medical facilities to raise awareness. Halberd is debt-free and holds exclusive rights to multiple patent-pending COVID-19 treatments, indicating a strong position in the healthcare market.

Halberd Corporation (OTC PINK:HALB) has filed a PCT application for its invention titled Method for Treating and Curing Covid-19 Infection. This filing allows patent protection in over 150 countries, enhancing its global reach. CEO William A. Hartman expressed confidence in their technology, which includes treatments using radiofrequency and laser methodologies. The initial U.S. provisional patent was filed on March 16, 2020. Halberd Corporation holds exclusive rights to various COVID-19 treatment patents and is committed to advancing its research despite uncertainties surrounding the pandemic.